{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T23:40:05Z","timestamp":1714088405314},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1097\/jcp.0b013e31825d380d","type":"journal-article","created":{"date-parts":[[2012,6,20]],"date-time":"2012-06-20T19:39:58Z","timestamp":1340221198000},"page":"492-502","source":"Crossref","is-referenced-by-count":12,"title":["Human Abuse Potential and Cognitive Effects of Taranabant, a Cannabinoid 1 Receptor Inverse Agonist"],"prefix":"10.1097","volume":"32","author":[{"given":"Kerri A.","family":"Schoedel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Addy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijan","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Rosko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Dunbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Maes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selwyn Aubrey","family":"Stoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Chodakewitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward M.","family":"Sellers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"5","key":"R1-9-20210128","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nn1457","article-title":"Endocannabinoid control of food intake and energy balance.","volume":"8","author":"Di Marzo","year":"2005","journal-title":"Nat Neurosci"},{"key":"R2-9-20210128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00008877-200509000-00004","article-title":"Endocannabinoids in the regulation of appetite and body weight.","volume":"16","author":"Kirkham","year":"2005","journal-title":"Behav Pharmacol"},{"key":"R3-9-20210128","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/ijo.2009.132","article-title":"Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions.","volume":"33","author":"Fong","year":"2009","journal-title":"Int J Obes (Lond)"},{"key":"R4-9-20210128","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ddr.20335","article-title":". CB1 receptor inverse agonist pharmacotherapy for metabolic disorders.","volume":"70","author":"Fong","year":"2009","journal-title":"Drug Dev Res"},{"key":"R5-9-20210128","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cmet.2007.11.012","article-title":". The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.","volume":"7","author":"Addy","year":"2008","journal-title":"Cell Metab"},{"key":"R6-9-20210128","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/09540260902782786","article-title":"Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders.","volume":"21","author":"Beardsley","year":"2009","journal-title":"Int Rev Psychiatry"},{"key":"R7-9-20210128","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1358\/dnp.2008.21.3.1203411","article-title":"The role of the endogenous cannabinoid system in drug addiction.","volume":"21","author":"Parolaro","year":"2008","journal-title":"Drug News Perspect"},{"key":"R9-9-20210128","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/FBP.0b013e3283423d7e","article-title":". MK-7128, a novel CB1 receptor inverse agonist, improves scopolamine-induced learning and memory deficits in mice.","volume":"22","author":"Dillon","year":"2011","journal-title":"Behav Pharmacol"},{"key":"R11-9-20210128","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/sj.npp.1301297","article-title":". Combination of rimonabant and donepezil prolongs spatial memory duration.","volume":"32","author":"Wise","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"R12-9-20210128","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.nlm.2010.01.010","article-title":". SLV330, a cannabinoid CB1 receptor antagonist, ameliorates deficits in the T-maze, object recognition and social recognition tasks in rodents.","volume":"93","author":"de Bruin","year":"2010","journal-title":"Neurobiol Learn Mem"},{"key":"R13-9-20210128","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/15622970801908047","article-title":"Potential antipsychotic properties of central cannabinoid (CB1R) receptor antagonists.","volume":"11","author":"Roser","year":"2010","journal-title":"World J Biol Psychiatry"},{"key":"R14-9-20210128","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/archpsyc.58.4.322","article-title":". Blockade of effects of smoked marijuana by the CB1R-selective cannabinoid receptor antagonist SR141716.","volume":"58","author":"Huestis","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"R15-9-20210128","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0014-2999(01)01597-7","article-title":". Evaluation of the reinforcing effects of the cannabinoid CB1 receptor antagonist, SR141716, in rhesus monkeys.","volume":"435","author":"Beardsley","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"R16-9-20210128","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ddr.20336","article-title":"Evaluation of taranabant (MK-0364) for its self-administration in rhesus monkeys and for its discriminative stimulus effects in rats.","volume":"70","author":"Beardsley","year":"2009","journal-title":"Drug Dev Res"},{"key":"R17-9-20210128","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1463-1326.2009.01188.x","article-title":". A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes.","volume":"12","author":"Kipnes","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"R18-9-20210128","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1177\/0091270008314467","article-title":". Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.","volume":"48","author":"Addy","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R19-9-20210128","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/0091270008317591","article-title":". Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.","volume":"48","author":"Addy","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R20-9-20210128","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","article-title":". Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.","volume":"368","author":"Scheen","year":"2006","journal-title":"Lancet"},{"key":"R22-9-20210128","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/1098-2396(200011)38:2<167::AID-SYN8>3.0.CO;2-W","article-title":". Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats.","volume":"38","author":"Rowley","year":"2000","journal-title":"Synapse"},{"key":"R23-9-20210128","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.drugalcdep.2008.01.008","article-title":". Abuse liability assessment of atomoxetine in a drug-abusing population.","volume":"95","author":"Jasinski","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"R24-9-20210128","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00004714-199806000-00008","article-title":". Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines.","volume":"18","author":"Cole","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"R25-9-20210128","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s002130050001","article-title":". Abuse liability assessment of sibutramine, a novel weight control agent.","volume":"147","author":"Schuh","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"R26-9-20210128","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure.","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"R27-9-20210128","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/hup.1196","article-title":". A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.","volume":"26","author":"Schoedel","year":"2011","journal-title":"Hum Psychopharmacol"},{"key":"R28-9-20210128","first-page":"149","article-title":"Experimental designs balanced for the estimation of residual effects of treatments.","volume":"2","author":"Williams","year":"1949","journal-title":"Aus J Sci Res Ser"},{"key":"R29-9-20210128","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00213-002-1169-0","article-title":". Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users.","volume":"164","author":"Curran","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"R30-9-20210128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0091-3057(98)00264-0","article-title":"Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users.","volume":"63","author":"Kirk","year":"1999","journal-title":"Pharmacol Biochem Behav"},{"key":"R31-9-20210128","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/clpt.2010.67","article-title":". Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.","volume":"88","author":"Schoedel","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R32-9-20210128","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cpt1971122part1245","article-title":". Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man.","volume":"12","author":"Martin","year":"1971","journal-title":"Clin Pharmacol Ther"},{"key":"R33-9-20210128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0376-8716(85)90002-X","article-title":"Hangover effects the morning after marijuana smoking.","volume":"15","author":"Chait","year":"1985","journal-title":"Drug Alcohol Depend"},{"key":"R34-9-20210128","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00005053-196509000-00006","article-title":"Addiction Research Center Inventory (ARCI): development of a general drug estimation scale.","volume":"141","author":"Haertzen","year":"1965","journal-title":"J Nerv Ment Dis"},{"key":"R35-9-20210128","first-page":"546","article-title":"When do professional psychologists need professional programmers tools Behav Res Methods Instrum Comput.","volume":"17","author":"Kaplan","year":"1985","journal-title":""},{"key":"R36-9-20210128","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1126\/science.153.3736.652","article-title":"High-speed scanning in human memory.","volume":"153","author":"Sternberg","year":"1966","journal-title":"Science"},{"key":"R38-9-20210128","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0376-8716(03)00098-X","article-title":"Principles of initial experimental drug abuse liability assessment in humans.","volume":"70","author":"Griffiths","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"R39-9-20210128","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/0165-6147(84)90415-2","article-title":"Abuse liability assessment in human subjects.","volume":"5","author":"Jasinski","year":"1984","journal-title":"Trends Pharmacol Sci"},{"key":"R40-9-20210128","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing.","volume":"571","author":"Benjamini","year":"1995","journal-title":"J R Statist Soc B"},{"key":"R41-9-20210128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF02245145","article-title":"Reinforcing and subjective effects of oral delta 9-THC and smoked marijuana in humans.","volume":"107","author":"Chait","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"key":"R42-9-20210128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00213-005-2234-2","article-title":". Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure.","volume":"181","author":"Hart","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"R43-9-20210128","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0091-3057(97)00414-0","article-title":"Effects of expectancies on subjective responses to oral delta9-tetrahydrocannabinol.","volume":"59","author":"Kirk","year":"1998","journal-title":"Pharmacol Biochem Behav"},{"key":"R44-9-20210128","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0893-133X(01)00273-1","article-title":". Effects of acute smoked marijuana on complex cognitive performance.","volume":"25","author":"Hart","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"R45-9-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF00735812","article-title":". Sensory, perceptual, motor and cognitive functioning and subjective reports following oral administration of delta9-tetrahydrocannabinol.","volume":"47","author":"Peters","year":"1976","journal-title":"Psychopharmacologia"},{"key":"R46-9-20210128","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.drugalcdep.2006.03.015","article-title":". Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment.","volume":"85","author":"Ramaekers","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"R47-9-20210128","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/sj.npp.1301643","article-title":". Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis.","volume":"33","author":"DSouza","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"R48-9-20210128","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/0269881108092393","article-title":". Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users.","volume":"23","author":"Ramaekers","year":"2009","journal-title":"J Psychopharmacol"},{"key":"R49-9-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2008.03.001","article-title":". The role of human drug self-administration procedures in the development of medications.","volume":"96","author":"Comer","year":"2008","journal-title":"Drug Alcohol Depend"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-201208000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T23:27:21Z","timestamp":1714087641000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201208000-00009"}},"subtitle":["A Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Study in Recreational Polydrug Users"],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31825d380d","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}